Your browser is no longer supported. Please, upgrade your browser.
We’ve redesigned our maps and bubbles! Read more about the new features here. ×
Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E51.22 EPS (ttm)1.20 Insider Own1.80% Shs Outstand1.66B Perf Week3.21%
Market Cap102.15B Forward P/E27.89 EPS next Y2.20 Insider Trans-2.23% Shs Float1.66B Perf Month-0.85%
Income2.00B PEG3.27 EPS next Q0.51 Inst Own72.40% Short Float1.29% Perf Quarter5.04%
Sales15.88B P/S6.43 EPS this Y-22.10% Inst Trans0.62% Short Ratio3.52 Perf Half Y22.67%
Book/sh8.95 P/B6.87 EPS next Y30.72% ROA6.00% Target Price63.88 Perf Year17.94%
Cash/sh4.47 P/C13.74 EPS next 5Y15.65% ROE13.20% 52W Range45.35 - 64.44 Perf YTD4.12%
Dividend1.48 P/FCF456.04 EPS past 5Y-5.90% ROI6.40% 52W High-4.89% Beta0.30
Dividend %2.41% Quick Ratio1.50 Sales past 5Y-3.30% Gross Margin76.20% 52W Low35.15% ATR1.04
Employees25000 Current Ratio1.70 Sales Q/Q-4.10% Oper. Margin22.20% RSI (14)56.95 Volatility1.64% 1.74%
OptionableYes Debt/Eq0.53 EPS Q/Q-97.70% Profit Margin12.60% Rel Volume0.40 Prev Close61.46
ShortableYes LT Debt/Eq0.49 EarningsJan 27 BMO Payout119.80% Avg Volume6.07M Price61.29
Recom2.30 SMA201.83% SMA501.54% SMA20014.94% Volume833,456 Change-0.28%
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Jan-10-14Upgrade Barclays Equal Weight → Overweight $52 → $65
Dec-20-13Reiterated UBS Neutral $48 → $54
Jul-29-13Reiterated Argus Buy $54
Jul-17-13Reiterated Barclays Equal Weight $42 → $45
Jun-04-13Reiterated Argus Buy $46 → $54
Apr-26-13Reiterated MKM Partners Sell $26 → $29
Apr-15-13Reiterated Barclays Equal Weight $33 → $42
Jan-25-13Reiterated UBS Neutral $34 → $36
Jan-09-12Reiterated Barclays Capital Overweight $34 → $36
Oct-19-11Initiated MKM Partners Sell $26
Jun-27-11Reiterated UBS Neutral $28 → $30
Mar-31-11Downgrade Jefferies Buy → Hold $28.50
Mar-28-11Reiterated Barclays Capital Overweight $28 → $30
Sep-22-10Reiterated Deutsche Bank Buy $28 → $31.50
Sep-01-10Reiterated UBS Neutral $26 → $27
Feb-26-15 03:15PM  Bristol hep C drug helps cure 97 pct of HIV coinfected patients-study Reuters
03:15PM  ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After Ribavirin-Free Investigational 12-Week Regimen of Daclatasvir and Sofosbuvir Business Wire
09:35AM  Rigel Pharma CEO pulls back the curtain on drug deal with Bristol-Myers at American City Business Journals
08:30AM  Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in Preventing Viral Replication via Different Mechanism of Action Than Current Therapies Business Wire
Feb-25-15 12:57PM  Bristol-Myers Squibb Launches Phase III Trial Of HIV Drug Benzinga
11:00AM  Eight Undervalued Key Antibiotics Players at Barrons.com
08:30AM  48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation Business Wire
Feb-24-15 06:54PM  Bristol-Myers to Buy Flexus, Team Up with Rigel - Analyst Blog Zacks
03:58PM  Lannett Joins Big-Game Hunt For Drugmaker Acquisitions at Investor's Business Daily
10:10AM  Stock Market News for February 24, 2015 - Market News Zacks
10:00AM  Bristol-Myers Squibb to Present at Cowen and Company Annual Global Health Care Conference Business Wire
Feb-23-15 05:00PM  Will Celldex Therapeutics (CLDX) Disappoint This Earnings? - Analyst Blog Zacks
02:59PM  Drugmaker Mylan Takes Part In Pharma Feeding Frenzy at Investor's Business Daily
12:41PM  Pharma M&A: Bristol-Myers, Valeant Make Deals at Investor's Business Daily
11:14AM  Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies at TheStreet
10:30AM  Bristol-Myers Squibb Foundation Awards GRU Cancer Center Three-Year, $1.74M Grant to Address Lung Cancer Among Neediest Communities in Central Savannah River Area Business Wire
10:19AM  Bristol-Myers Makes $1.6 Billion in Deals Boosting Cancer Focus at Bloomberg
09:48AM  Bristol-Myers adds to cancer-treatment push with acquisition AP
09:15AM  Is Rigel Getting Enough From Bristol-Meyers? at 24/7 Wall St.
09:11AM  U.S. stocks: Futures dip as oil slide hits energy companies at MarketWatch
08:45AM  Bristol-Myers to Acquire Flexus Immunotherapy Pipeline at The Wall Street Journal
08:18AM  Bristol-Myers buys Flexus Biosciences in a deal worth up to $1.25 billion at MarketWatch
08:10AM  Bristol-Myers to buy private cancer drugmaker for up to $1.25 bln Reuters
08:03AM  Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications PR Newswire
08:00AM  Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications Business Wire
08:00AM  Bristol-Myers Squibb To Expand Its Immuno-Oncology Pipeline with Agreement to Acquire Flexus Biosciences, Inc. Business Wire
Feb-20-15 01:04PM  BRISTOL MYERS SQUIBB CO Financials EDGAR Online Financials
Feb-19-15 05:58AM  Candidate to lead FDA has close ties to big pharma at Fortune
Feb-18-15 05:50PM  Seattle Genetics' SEA-CD40 Enters Phase I for Solid Tumors - Analyst Blog Zacks
Feb-17-15 10:42AM  Cramer: Greece situation unlike the old days at CNBC
08:30AM  Global Pharma's R&D Re-Balancing at Forbes
Feb-16-15 03:10PM  Merck KGaA to Gain Full Marketing Rights to Erbitux in Japan - Analyst Blog Zacks
Feb-15-15 07:07PM  10-K for Bristol-Myers Squibb Co. Company Spotlight
Feb-13-15 09:39AM  BRISTOL MYERS SQUIBB CO Files SEC form 10-K, Annual Report EDGAR Online
Feb-11-15 09:18AM  Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog Zacks
06:10AM  The Coming Boom In Brain Medicines at Forbes
Feb-10-15 03:43PM  Canadian government to require drug shortage notice Reuters
06:00AM  'Mad Money' Lightning Round: Take Nucor Over United States Steel at TheStreet
06:00AM  Jim Cramer's Top Stock Picks: TWTR BMY NUE WFC at TheStreet
Feb-09-15 07:03PM  Cramer Remix: What this oil price means for you at CNBC
06:58PM  Lightning Round: This industry had a run-don't buy at CNBC
06:00PM  Cramer: What this oil price means for you CNBC
Feb-07-15 12:01AM  AbbVie: Big Pharma at a Discount Price at Barrons.com
Feb-06-15 09:02AM  AstraZeneca Lags Q4 Earnings, to Boost Respiratory Portfolio - Analyst Blog Zacks
Feb-05-15 11:00AM  Big Pharma Weak Guidance Put These ETFs in Focus - ETF News And Commentary Zacks
09:30AM  Bristol-Myers Squibb to Take Part in Leerink Swann Global Health Care Conference Business Wire
Feb-04-15 03:55PM  In speed mode, FDA approves Pfizers big new drug early at Fortune
Jan-30-15 05:25PM  Celldex/Bristol-Myers Initiate Phase I/II Solid Tumor Study - Analyst Blog Zacks
03:59PM  US profitability: the rich list at Financial Times
Jan-29-15 05:19PM  U.S. Food and Drug Administration Approves Bristol-Myers Squibbs Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults Business Wire
08:00AM  Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo(R) in Advanced Refractory Solid Tumors GlobeNewswire
Jan-28-15 10:10AM  Company News for January 28, 2015 - Corporate Summary Zacks
Jan-27-15 06:10PM  Drug Firms Report Good Q4, But Outlook Cloudy at Investor's Business Daily
06:00PM  Cramer: I've never seen anything like this CNBC
05:31PM  Updates, advisories and surprises at MarketWatch
02:39PM  Strong Dollar Means Flabby Outlook For Some Overseas at Investor's Business Daily
01:48PM  Cancer Drugs Boost Bristol-Myers Sales at The Wall Street Journal
01:05PM  Midday movers: Lockheed Martin, Plantronics & more at CNBC
12:42PM  Bristol-Myers Squibb (BMY) Stock Falls Today on Weak Guidance at TheStreet
11:57AM  Bristol, Pfizer, Novartis Forecasts Face FX Pressures at Investor's Business Daily
11:09AM  Pfizer Edges Ahead On Q4, Even As Forecast Falls Short at Barrons.com
10:51AM  Bristol-Myers Beats on Q4 Earnings, 2015 View Disappoints - Analyst Blog Zacks
09:29AM  Bristol-Myers says strong dollar drags on 2015 outlook Reuters
09:11AM  Bristol-Myers issues cautious 2015 forecast due to strong dollar Reuters
08:44AM  Bristol-Myers (BMY) Beats on Q4 Earnings and Revenues - Tale of the Tape Zacks
08:38AM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E EDGAR Online
08:06AM  Bristol-Meyers beats fourth quarter expectations, but stock dips after dissappointing outlook at MarketWatch
07:58AM  Pension charge, lower sales slash Bristol-Myers' Q4 profit AP
07:56AM  Bristol-Myers quarterly profit beats forecasts Reuters
07:56AM  Bristol-Myers beats Street 4Q forecasts AP
07:33AM  Bristol-Myers 2015 Sales Forecast Stymied by Dollars Strength at Bloomberg
07:30AM  Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2014 Financial Results Business Wire
07:07AM  Q4 2014 Bristol-Myers Squibb Co Earnings Release - Before Market Open CCBN
Jan-26-15 04:45PM  CytRx Candidate Encourages in Soft Tissue Sarcoma Study - Analyst Blog Zacks
03:29PM  What to Expect When Bristol-Myers Squibb (BMY) Reports Fourth-Quarter Earnings Tomorrow at TheStreet
06:47AM  Cramer: Don't Be Afraid of the Greek Vote TheStreet
Jan-23-15 04:34PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem EDGAR Online
03:50PM  Will Oncology Products Drive Bristol-Myers (BMY) Earnings? - Analyst Blog Zacks
06:15AM  Up to Speed: Death of Saudi king moves needle on oil prices (Video) at American City Business Journals
Jan-22-15 07:44PM  Lightning Round: Only private equity I recommend at CNBC
Jan-21-15 06:13PM  Bristol-Myers Makes Leadership Changes, Names New CEO - Analyst Blog Zacks
11:46AM  The Lone Biotech Bear? at Forbes
06:33AM  p53, Immunology and Antibody Drug Conjugate Therapies Bringing More Powerful Weapons to Battlefield in the War on Cancer Company Spotlight
Jan-20-15 08:17PM  Bristol-Myers Operating Chief to Become CEO in May at The Wall Street Journal
07:26PM  Bristol-Myers Squibb CEO steps down, replaced by COO at Fortune
06:17PM  Bristol-Myers Operating Chief to Become CEO at The Wall Street Journal
05:47PM  Bristol-Myers names Caforio as CEO AP
05:29PM  Bristol-Meyers Squibb taps a doctor as new CEO at CNBC
05:22PM  Bristol-Myers taps insider Caforio as next CEO Reuters
04:52PM  Bristol-Myers Names New CEO at Barrons.com
04:40PM  Bristol-Myers Squibb names Giovanni Caforio CEO, effective May 5 at MarketWatch
04:38PM  Bristol-Myers Names New CEO as Andreotti Becomes Chairman at Bloomberg
04:35PM  Bristol-Myers Squibb gets new CEO CNBC
04:30PM  Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become Chairman Business Wire
01:37PM  Investing in the Next Apple: 4 Boring But Innovative Companies to Buy Now at TheStreet
Jan-16-15 09:17AM  Jim Cramer on Europe and Why He's an 'America First' Stock Picker at TheStreet
Jan-15-15 06:14PM  Cramer: Forget Switzerland! Make big bucks in USA at CNBC
11:02AM  Eli Lilly Has 'Turned The Corner,' Upgraded at Investor's Business Daily
09:01AM  Cramer: Swiss move traumatizing CNBC
06:45AM  Stakes High for AstraZeneca Heart Drug Facing Tough Competition at Bloomberg
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company's principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliance with OliPass Corporation to discover and develop therapeutics against various targets using OliPass' technology platform. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Option Exercise25.4515,000381,750275,656Feb 18 05:32 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Sale60.3911,746709,282263,910Feb 18 05:32 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 12Sale59.263,880229,93334,480Feb 13 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 06Option Exercise22.1427,938618,54759,838Feb 10 06:11 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 06Sale60.1521,4781,291,98838,360Feb 10 06:11 PM
CORNELIUS JAMES MDirectorJan 30Sale60.6050,0003,029,975119,464Feb 03 06:18 PM
ANDREOTTI LAMBERTOChief Executive OfficerJan 29Option Exercise25.45112,5002,863,125473,309Feb 02 07:05 PM
CAMPBELL LEWIS BDirectorJan 29Option Exercise26.252,50065,6252,500Feb 02 07:05 PM
CAMPBELL LEWIS BDirectorJan 29Sale60.892,500152,2270Feb 02 07:05 PM
Schmukler Louis SPres., Global Mfg. & SupplyJan 29Sale60.735,250318,85014,182Feb 02 07:05 PM
ANDREOTTI LAMBERTOChief Executive OfficerJan 29Sale61.1490,2465,518,001383,063Feb 02 07:05 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00952050,808Jan 06 06:56 PM
ANDREOTTI LAMBERTOChief Executive OfficerDec 05Sale60.3175,0004,522,944360,809Dec 05 05:39 PM
ANDREOTTI LAMBERTOChief Executive OfficerNov 05Sale57.7975,0004,334,153435,809Nov 07 05:13 PM
Cuss Francis MEVP & CSONov 02Option Exercise0.006,6660245,112Nov 04 05:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,102099,666Nov 04 05:43 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 24Sale53.0050,0002,650,000510,809Oct 28 04:23 PM
CORNELIUS JAMES MDirectorOct 15Sale48.92100,0004,892,000169,041Oct 17 05:16 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 06Sale50.9950,0002,549,485560,809Oct 08 06:02 PM
Schmukler Louis SPres., Global Mfg. & SupplyOct 03Option Exercise0.0013,934025,565Oct 06 05:52 PM
Cuss Francis MEVP & CSOSep 16Option Exercise25.1763,6671,602,575302,113Sep 16 05:18 PM
Cuss Francis MEVP & CSOSep 16Sale50.7763,6673,232,074238,446Sep 16 05:18 PM
Caforio GiovanniChief Operating OfficerSep 15Sale49.8726,6911,331,15540,755Sep 16 05:18 PM
Caldarella Joseph CSVP & ControllerSep 10Sale51.037,415378,37761,550Sep 10 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerSep 08Sale51.0550,0002,552,430610,809Sep 10 04:30 PM
von Autenried PaulSVP, Enterp. Services & CIOAug 19Sale49.8920,000997,85137,523Aug 19 05:08 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Option Exercise27.0119,650530,74759,652Jul 30 04:40 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Sale49.3225,7521,270,03733,900Jul 30 04:40 PM
DANIELS BRIANSVP Global Dev & Med AffairsJul 01Option Exercise0.004,671096,477Jul 02 06:35 PM
ANDREOTTI LAMBERTOChief Executive OfficerMay 05Option Exercise0.0013,9900662,469May 06 09:17 PM
Elicker John ESVP Pub Affairs & Inv RelationMay 03Option Exercise0.001,509050,536May 05 05:05 PM
Moed Samuel JSVP, Strat Plan & AnalysisMay 01Option Exercise0.005,000042,595May 02 04:18 PM
JUDGE ANN POWELLSVP, Human ResourcesApr 01Option Exercise0.001,55403,693Apr 03 04:17 PM
Caldarella Joseph CSVP & ControllerMar 13Sale55.209,137504,36268,965Mar 13 04:32 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.002,739058,345Mar 12 04:54 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.004,8780262,120Mar 12 04:52 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.001,173037,948Mar 12 04:53 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.00688043,432Mar 12 04:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.002,739011,600Mar 12 04:53 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.002,7390239,268Mar 12 04:51 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 10Option Exercise0.002,528092,314Mar 12 04:51 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.001,850049,399Mar 12 04:52 PM
Heller Frances KSVP, Business DevelopmentMar 10Option Exercise0.001,60904,402Mar 12 04:52 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.002,10702,107Mar 12 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.006,4100165,472Mar 12 04:50 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 10Option Exercise0.004,878068,910Mar 12 04:51 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.001,850078,768Mar 12 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0027,6130658,396Mar 12 04:50 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Sale55.52100,0005,552,260630,783Mar 10 04:40 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Sale55.818,799491,0638,861Mar 10 04:43 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528017,224Mar 10 04:43 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390056,064Mar 10 04:43 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043036,841Mar 10 04:42 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 06Option Exercise0.003,010090,018Mar 10 04:41 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043047,630Mar 10 04:42 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400738,383Mar 10 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230159,626Mar 10 04:40 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 06Option Exercise0.002,889064,586Mar 10 04:40 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931077,422Mar 10 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100237,106Mar 10 04:41 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724042,756Mar 10 04:42 PM
CORNELIUS JAMES MDirectorMar 05Sale55.82100,0005,582,000273,393Mar 05 04:40 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 03Option Exercise0.0099,9370292,758Mar 05 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 03Option Exercise0.0015,209040,530Mar 05 04:39 PM
Nielsen AnneChief Compliance & Ethics OffMar 03Option Exercise0.0013,132046,648Mar 05 04:39 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 03Option Exercise0.0017,471051,061Mar 05 04:37 PM
Cuss Francis MEVP & CSOMar 03Option Exercise0.0047,9530254,899Mar 05 04:36 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 03Option Exercise0.0050,3260103,410Mar 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 03Option Exercise0.00121,0140199,850Mar 05 04:35 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 03Option Exercise0.0018,875068,527Mar 05 04:36 PM
Caldarella Joseph CSVP & ControllerMar 03Option Exercise0.0031,053089,900Mar 05 04:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 03Option Exercise0.00423,5330912,318Mar 05 04:35 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 03Option Exercise0.0039,420068,820Mar 05 04:40 PM
Schmukler Louis SPres., Global Mfg. & SupplyFeb 28Sale54.496,088331,73614,696Feb 28 04:44 PM